MAGLE Stock Overview
Operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Magle Chemoswed Holding AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 42.40 |
52 Week High | SEK 49.80 |
52 Week Low | SEK 21.40 |
Beta | 0.63 |
11 Month Change | 25.44% |
3 Month Change | 30.86% |
1 Year Change | 39.47% |
33 Year Change | 9.00% |
5 Year Change | n/a |
Change since IPO | 106.73% |
Recent News & Updates
Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher
Jun 26Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet
Jun 19Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Recent updates
Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher
Jun 26Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet
Jun 19Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings
Oct 05Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?
Jan 22Shareholder Returns
MAGLE | SE Life Sciences | SE Market | |
---|---|---|---|
7D | -7.8% | -0.8% | -1.0% |
1Y | 39.5% | 15.4% | 13.3% |
Return vs Industry: MAGLE exceeded the Swedish Life Sciences industry which returned 15.4% over the past year.
Return vs Market: MAGLE exceeded the Swedish Market which returned 13.3% over the past year.
Price Volatility
MAGLE volatility | |
---|---|
MAGLE Average Weekly Movement | 7.7% |
Life Sciences Industry Average Movement | 7.7% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.3% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: MAGLE's share price has been volatile over the past 3 months.
Volatility Over Time: MAGLE's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1944 | 78 | Justin Pierce | www.maglechemoswed.com |
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company’s microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures.
Magle Chemoswed Holding AB (publ) Fundamentals Summary
MAGLE fundamental statistics | |
---|---|
Market cap | SEK 457.92m |
Earnings (TTM) | SEK 12.23m |
Revenue (TTM) | SEK 171.17m |
37.4x
P/E Ratio2.7x
P/S RatioIs MAGLE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MAGLE income statement (TTM) | |
---|---|
Revenue | SEK 171.17m |
Cost of Revenue | SEK 17.18m |
Gross Profit | SEK 153.99m |
Other Expenses | SEK 141.76m |
Earnings | SEK 12.23m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 18, 2024
Earnings per share (EPS) | 1.13 |
Gross Margin | 89.96% |
Net Profit Margin | 7.14% |
Debt/Equity Ratio | 36.3% |
How did MAGLE perform over the long term?
See historical performance and comparison